Abstract: Objective To observe the therapeutic efficacy and safety of recombinant tissue-type plasminogen activator (rt-PA) combined with edaravone on acute cerebral infarction (ACI).Methods 60 cases of ACI were divided into rt-PA group (30 cases, treated by rt-PA only) and trial group (30 cases, treated with rt-PA combined with edaravone). The nerve function deficits of patients in both groups were evaluated by European Stroke Scale (ESS) and Barthel Index (BI) before and after treatment respectively.Results The ESS scores at 21st day and 90th day after treatment in the trial group were significantly higher than those of the patients in the rt-PA group. The effective rate of patients in the trial group was significantly higher than those in the rt-PA group (P＜0.05).Conclusion The treatment of rt-PA combined with edaravone is effective and safe in patients with ACI.

Key words: recombinant tissue-type plasminogen activator (rt-PA), edaravone, acute cerebral infarction